{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:38:38Z","timestamp":1790829518150,"version":"4.1.0"},"reference-count":27,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,7,24]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Lipoprotein(a) (Lp(a)) is associated with an increased incidence of native aortic stenosis, which shares similar pathological mechanisms with bioprosthetic aortic valve (bAV) degeneration. However, evidence regarding the role of Lp(a) concentrations in bAV degeneration is lacking. This study aims to evaluate the association between Lp(a) concentrations and bAV degeneration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective multicentre study, patients who underwent a bAV replacement between 1 January 2010 and 31 December 2020 and had a Lp(a) measurement were included. Echocardiography follow-up was performed to determine the presence of bioprosthetic valve degeneration, which was defined as an increase &gt;10\u2009mm\u2009Hg in mean gradient from baseline with concomitant decrease in effective orifice area and Doppler Velocity Index, or new moderate\/severe prosthetic regurgitation. Levels of Lp(a) were compared between patients with and without degeneration and Cox regression analysis was performed to investigate the association between Lp(a) levels and bioprosthetic valve degeneration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 210 cases were included (mean age 74.1\u00b19.4 years, 72.4% males). Median time between baseline and follow-up echocardiography was 4.4 (IQR 3.7) years. Bioprostheses degeneration was observed in 33 (15.7%) patients at follow-up. Median serum levels of Lp(a) were significantly higher in patients affected by degeneration versus non-affected cases: 50.0 (IQR 72.0) vs 15.6 (IQR 48.6) mg\/dL, p=0.002. In the regression analysis, high Lp(a) levels (\u226530\u2009mg\/dL) were associated with degeneration both in a univariable analysis (HR 3.6, 95% CI 1.7 to 7.6, p=0.001) and multivariable analysis adjusted by other risk factors for bioprostheses degeneration (HR 4.4, 95% CI 1.9 to 10.4, p=0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>High serum Lp(a) is associated with bAV degeneration. Prospective studies are needed to confirm these findings and to investigate whether lowering Lp(a) levels could slow bioprostheses degradation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2023-322987","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T05:05:14Z","timestamp":1693285514000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-8485","authenticated-orcid":false,"given":"Juan M","family":"Farina","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Ju","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Pereyra","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roarke","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebram F","family":"Said","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Barry","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Sell-Dottin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Fortuin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae K","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Marcotte","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"2025101715044382000_110.4.299.1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-307020"},{"key":"2025101715044382000_110.4.299.2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ehjci\/jeac274","article-title":"Serum Lipoprotein(A) and Bioprosthetic aortic valve degeneration","volume":"24","author":"Botezatu","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025101715044382000_110.4.299.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.064"},{"key":"2025101715044382000_110.4.299.4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018506","article-title":"Degeneration of Bioprosthetic heart valves: update 2020","volume":"9","author":"Kostyunin","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025101715044382000_110.4.299.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.715"},{"key":"2025101715044382000_110.4.299.6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890.2020.1775287","article-title":"Lipoprotein(A) in Atherosclerosis: from pathophysiology to clinical relevance and treatment options","volume":"52","author":"Rehberger Likozar","year":"2020","journal-title":"Ann Med"},{"key":"2025101715044382000_110.4.299.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.07.020"},{"key":"2025101715044382000_110.4.299.8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(A) and Calcific aortic valve stenosis: A systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2025101715044382000_110.4.299.9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41587-022-01396-x","article-title":"RNA drugs lower Lipoprotein(A) and genetically driven cholesterol","volume":"40","author":"Sheridan","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2025101715044382000_110.4.299.10","first-page":"975","article-title":"Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: a report from the American society of echocardiography\u2019s guidelines and standards committee and the task force on prosthetic valves, developed in conjunction with the American college of cardiology cardiovascular imaging Committee, cardiac imaging committee of the American heart Association","volume":"22","author":"Zoghbi","year":"2009","journal-title":"The European Association of Echocardiography, a Registered Branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, Endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a Registered Branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography J Am Soc Echocardiogr"},{"key":"2025101715044382000_110.4.299.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030729"},{"key":"2025101715044382000_110.4.299.12","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jew025"},{"key":"2025101715044382000_110.4.299.13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.hlc.2019.09.013","article-title":"Patient risk factors for Bioprosthetic aortic valve degeneration: A systematic review and meta-analysis","volume":"29","author":"Ochi","year":"2020","journal-title":"Heart Lung Circ"},{"key":"2025101715044382000_110.4.299.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.01.027"},{"key":"2025101715044382000_110.4.299.15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jama.2021.3632","article-title":"Lipoprotein(A) and cardiovascular diseases","volume":"326","author":"Miksenas","year":"2021","journal-title":"JAMA"},{"key":"2025101715044382000_110.4.299.16","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1093\/eurheartj\/ehac436","article-title":"Lipoprotein(A) and aortic valve stenosis: work in progress","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2025101715044382000_110.4.299.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.038"},{"key":"2025101715044382000_110.4.299.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109034"},{"key":"2025101715044382000_110.4.299.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026103"},{"key":"2025101715044382000_110.4.299.20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamacardio.2017.4266","article-title":"Association of LPA variants with aortic stenosis: A large-scale study using diagnostic and procedural codes from electronic health records","volume":"3","author":"Chen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025101715044382000_110.4.299.21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jacbts.2020.06.012","article-title":"Interaction of Autotaxin with Lipoprotein(A) in patients with Calcific aortic valve stenosis","volume":"5","author":"Bourgeois","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2025101715044382000_110.4.299.22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/HCO.0000000000000372","article-title":"Incidence, risk factors, clinical impact, and management of Bioprosthesis structural valve degeneration","volume":"32","author":"C\u00f4t\u00e9","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"2025101715044382000_110.4.299.23","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(A) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur Heart J"},{"key":"2025101715044382000_110.4.299.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010400"},{"key":"2025101715044382000_110.4.299.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.01.017"},{"key":"2025101715044382000_110.4.299.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.09.030"},{"key":"2025101715044382000_110.4.299.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.059"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2023-322987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:04:49Z","timestamp":1760738689000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2023-322987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/heartjnl-2023-322987"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2023-322987","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]}}}